Amgen Inc. (AMGN)
| Market Cap | 165.46B |
| Revenue (ttm) | 29.53B |
| Net Income (ttm) | 3.76B |
| Shares Out | 536.43M |
| EPS (ttm) | 7.01 |
| PE Ratio | 44.00 |
| Forward PE | 14.74 |
| Dividend | $9.00 (2.92%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 1,558,235 |
| Open | 312.15 |
| Previous Close | 310.15 |
| Day's Range | 307.06 - 312.61 |
| 52-Week Range | 211.71 - 329.72 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 304.89 (-1.15%) |
| Earnings Date | May 2, 2024 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $304.89, which is a decrease of -1.15% from the latest price.
News
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the luc...
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.
Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?
Amgen stock (NASDAQ NASDAQ : AMGN) has seen a solid 9% rise in a week, outperforming the broader S&P500 index, up 1.5%. The recent rise can be attributed to the progress with its weight-loss drug — Ma...
Dr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or better
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss Amgen's new injectable weight loss drugs, how it takes a different approach from other weight loss drugs like Wegovy and Mounja...
Weight-loss injection drug boosts Amgen
Amgen investors are getting a healthy diagnosis after the company reported strong earnings and announced promising developments for its weight-loss injection.
Amgen (AMGN) Sales Higher After Obesity Drug Results
Amgen (AMGN) sales are higher after early results from a study of an obesity drug. Renita Young discusses this as the Amgen CEO is “very encouraged” by the results of the obesity drug study.
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Amgen Shares Soar on Obesity Drug Progress
Amgen's shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company's experimental obesity drug, MariTide. Simone Foxman reports.
Cramer's Mad Dash: Amgen
CNBC's Jim Cramer delivers his daily Mad Dash.
Amgen's obesity-drug stock surge still in ‘early innings,' analysts say
Fueled by upbeat management comments on an experimental obesity treatment, Amgen's stock jumped more than 12% early Friday — and analysts see more gains ahead as the company maps out late-stage trials...
Dow Jones Today: Stock Futures Higher Ahead of Jobs Data; Apple, Amgen Surging
U.S. stock futures were solidly higher Friday morning as investors digested a slew of earnings reports and awaited the monthly U.S. employment report.
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its e...
Amgen shares jump after teasing 'encouraging' weight loss data
U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company teased encouraging data for its experimental obesity drug, igniting investor hopes but leaving Wall Street frustr...
Amgen Stock Jumps on Obesity Drug Optimism. What Comes Next.
The company is trying to carve a niche in a rapidly growing obesity-drug market that's currently dominated by Eli Lilly and Novo Nordisk.
Amgen Stock Surges After Q1 Earnings Beat, 'Encouraging' Weight-Loss Drug Update
Amgen (AMGN) shares surged more than 14% in extended-hours trading on Thursday after the biopharmaceutical giant posted quarterly earnings that came in ahead of Wall Street expectations and provided a...
Amgen expects data from weight-loss drug trial later this year
Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectations and said that plans for further trials for its weight-loss d...
Amgen scraps experimental weight loss pill, moves forward with injection
Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Amgen first-quarter profit dips 1%, revenue rises 22%
Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially off...
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , May 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
Moody's, Booking, DraftKings, Amgen stocks in focus ahead of earnings
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and Nas...
Amgen investors await weight-loss drug data
Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Findings From Tezspire ® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS ® (avacopan) Data in Adults With Sev...
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the...